Table 4.

Comparison of positivity rate between primary and metastatic breast cancer tumors for each antibody

	Primary tumor	Metastatic tumor	P‐value
Total breast tumors, n (%)	20 (100)	23 (100)
CNB specimens	5 (25)	1 (4)
Surgical specimens	15 (75)	22 (96)
TIL positivity rate, median % (range)
CD4	40 (<10–77)	25 (<10–83)	0.03
CD8	16 (<10–37)	10 (<10–37)	0.01
Foxp3	<10 (<10–10)	<10 (<10)	0.16
PD‐L1	<10 (<10–90)	<10 (<10–15)	0.21
PD‐L2	42 (<10–80)	30 (<10–80)	0.09
Expression in tumor cells, n (%)
PD‐L1
Strong: 2	8 (40)	5 (25)	0.46
Weak: 1	10 (50)	15 (75)
Negative: 0	2 (10)	3 (15)
PD‐L2
Strong: 2	6 (30)	9 (45)	0.78
Weak: 1	10 (50)	11 (55)
Negative: 0	4 (20)	3 (15)
HLA
Strong: 2	4 (20)	6 (30)	0.89
Weak: 1	14 (70)	15 (75)
Negative: 0	2 (10)	2 (10)

CNB, core needle biopsy; PD‐L1/2, programmed cell death ligand 1/2; TIL, tumor‐infiltrating lymphocyte.